

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
10/821,125	04/08/2004	Mike Favet	GUID.119PA	8214		
51294 7590 06/27/2007 HOLLINGSWORTH & FUNK, LLC 8009 34TH AVE S. SUITE 125 MINNEAPOLIS, MN 55425		EXAMINER				
			MALAMUD, DEBORAH LESLIE			
		•	ART UNIT	PAPER NUMBER		
		·	3766			
			•			
			MAIL DATE	DELIVERY MODE		
			06/27/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/821,125	FAVET ET AL.	
Examiner	Art Unit	
Deborah Malamud	3766	

	- Administra		1
*	Deborah Malamud	3766	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence ado	lress
THE REPLY FILED <u>04 June 2007</u> FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR A	LOWANCE.	
1. The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance time periods:	wing replies: (1) an amendment, aff tice of Appeal (with appeal fee) in o ce with 37 CFR 1.114. The reply mo	idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A	dvisory Action, or (2) the date set forth		
no event, however, will the statutory period for reply expire is Examiner Note: If box 1 is checked, check either box (a) or	(b). ONLY CHECK BOX (b) WHEN THE		
TWO MONTHS OF THE FINAL REJECTION. See MPEP 70 Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	on which the petition under 37 CFR 1.1 tension and the corresponding amount shortened statutory period for reply origon than three months after the mailing da	of the fee. The approprinally set in the final Offi	iate extension fee ce action; or (2) as
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	ns of the date of the appeal. Since
AMENDMENTS	the state of the s		
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE below)	nsideration and/or search (see NO		ecause
(c) They are not deemed to place the application in being appeal; and/or		ducing or simplifying	the issues for
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		ected claims.	
4. The amendments are not in compliance with 37 CFR 1.1		mnliant Amendment	(PTOL-324)
5. Applicant's reply has overcome the following rejection(s)		inpliant / incliancie	(1 102 024).
Newly proposed or amended claim(s) would be all non-allowable claim(s).	•	timely filed amendme	ent canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is protected. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:		II be entered and an o	explanation of
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).	at before or on the date of filing a N d sufficient reasons why the affidat	otice of Appeal will <u>ne</u> vit or other evidence i	ot be entered s necessary and
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe y and was not earlier presented. S	al and/or appellant fa ee 37 CFR 41.33(d)(ils to provide a 1).
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attac	hed.
 The request for reconsideration has been considered bu <u>See Continuation Sheet.</u> 		n condition for allowa	nce because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08) Paper No(s).		
13. Other:	Cant X	LAYNO	
	CARL	LAYNO	
	PRIMARY	EXAMINER	

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06) Continuation of 11. does NOT place the application in condition for allowance because: The applicant argues (page 14, "Remarks") that "not only does Gill (previously cited reference) fail to disclose a non-physiologic, life sustaining pacing therapy, but Gill's disclosure of a bradycardia therapy diverges from a teaching of a non-physiologic, life sustaining pacing therapy, such that the two therapies would be understood to be materially different by one having ordinary skill in the art." The examiner respectfully disagrees. The applicant's disclosure, which is quoted in the applicant's arguments, is only one option known in the art of pacing therapy to be non-physiologic pacing therapy. Gill's device, as illustrated in previously cited paragraphs, discloses another method of treatment for asystole that comprises a non-physiologic, life sustaining pacing therapy, as required by claim 1, and as explained in previously cited paragraphs within Gill's disclosure. The applicant further argues the necessity of a Restriction requirement (pages 16-17, "Remarks"). The examiner would again like to note that though the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. As it pertains to the restriction requirement, the energy delivery circuitry of claim 1 administers a different therapy strategy, in response to a different, more specific cardiac condition than that required by the energy delivery circuitry of claim 16. Since the two inventions (group I and group II, including base claims 1 and 16 respectively) comprise different energy delivery circuitry and control circuitry and treat different conditions with different strategies, group I has a separate utility from group I, and therefore the restriction is deemed proper.